Item 1.01 Entry into a Material Definitive Agreement
Private Placement Offering
On November 29, 2022, Theralink Technologies, Inc. (the "Company") consummated
the initial closing (the "Initial Closing") of a private placement offering (the
"Offering") pursuant to the terms and conditions of that certain Securities
Purchase Agreement, dated as of November 29, 2022 (the "Purchase Agreement"), by
and among the Company, certain accredited investors (the "Purchasers") and
Cavalry Fund I Management LLC, a Delaware limited liability company, in its
capacity as collateral agent (the "Collateral Agent"). At the Initial Closing,
the Company sold the Purchasers (i) 10% Original Issue Discount Senior Secured
Convertible Debentures (the "Debentures") in an aggregate principal amount of
$3,355,000 and (ii) warrants (the "Warrants" and together with the Debentures,
the "Underlying Securities") to purchase up to 958,571,426 shares of common
stock of the Company (the "Common Stock"), subject to adjustments provided by
the Warrants, which represents 100% warrant coverage. The Company received a
total of $3,050,000 in gross proceeds at the Initial Offering, taking into
account the 10% original issue discount, before deducting offering expenses and
commissions.
The Company may hold one or more subsequent closings at any time prior to
December 31, 2022, unless otherwise extended, to sell additional Underlying
Securities in an aggregate principal amount up to $6,600,000, which may be
adjusted upward to mean an aggregate principal amount of $8,000,000 upon written
consent of the Company and the Placement Agent (as defined below).
The Purchase Agreement contains customary representations, warranties, and
covenants of the Company, including, among other things and subject to certain
exceptions, covenants that restrict the ability of the Company without the prior
written consent of the Debenture holders, to incur additional indebtedness, and
repay outstanding indebtedness, create or permit liens on assets, redeem its
Common Stock, settle outstanding litigation, or enter into transactions with
affiliates.
In connection with the Initial Closing, the Company and Joseph Gunnar & Co. LLC,
a U.S. registered broker-dealer ("Gunnar"), entered into a placement agency
agreement (the "Placement Agency Agreement" ), pursuant to which Gunnar agreed
to act as the placement agent for the Offering (the "Placement Agent"). Pursuant
to the terms of the Placement Agency Agreement, the Company agreed to (i) pay
Gunnar a cash placement fee of 10% of the gross cash proceeds raised in the
Offering, and (ii) issue to Gunnar warrants (the "PA Warrants") on the terms
identical to the Warrants sold in the Offering in an amount equal to 10% of the
Underlying Securities sold to investors.
As a result of the foregoing, the Company paid Gunnar an aggregate commission of
$305,000 in connection with the Initial Closing. The Company also paid $50,000
in fees to Gunnar's legal counsel and paid Gunnar a financial advisory fee of
$50,000.
Each investor in any subsequent closing will be required to represent that, at
the time of the applicable closing, it is an accredited investor as defined in
Rule 501(a) under the Securities Act of 1933, as amended (the "Securities Act")
and that there was no general solicitation or advertising in connection with the
Offering.
Debentures
The Debentures mature on November 29, 2023, subject to a three-month extension
at the sole discretion of the Company. The Debentures bear interest at 10% per
annum payable upon conversion or maturity. The Debentures are convertible into
shares of Common Stock at any time after the maturity date and prior to
Mandatory Conversion (as defined below) at the conversion price equal to the
lesser of: (i) $0.003 per share and (ii) 70% of the average of the VWAP (as
defined in the Debentures) (or 50% of the average of such VWAP if an event of
default has occurred and has not been cured) of the Common Stock during the ten
Trading Day (as defined in the Debentures) period immediately prior to the
applicable conversion date. The Debentures are subject to mandatory conversion
("Mandatory Conversion") in the event the Company closes a registered public
offering of its Common Stock and receives gross proceeds of not less than
$5,000,000, with such offering resulting in the listing for trading of the
Common Stock on a national exchange ("Qualified Offering"). The conversion price
per share of Common Stock in the case of a Mandatory Conversion shall be the
lesser of (i) $0.003 per share and (ii) 70% of the offering price per share in
the Qualified Offering (the "Qualified Offering Price"). Alternatively, upon a
Mandatory Conversion, the holders of the Debentures may elect to exchange their
Debentures for newly issued convertible preferred securities at a price per
share equal to the Qualified Offering Price or the five-day VWAP of the Common
Stock prior to the date that is 181 days after the closing of the Qualified
Offering.
Notwithstanding the preceding, holders of Debentures shall have the right to
require satisfaction of up to 40% of all amounts outstanding under the
Debentures, in cash, at the time of a Qualified Financing. The Debentures also
contain certain price protection provisions providing for adjustment of the
number of shares of Common Stock issuable upon conversion of the Debentures in
case of certain future dilutive events or stock-splits and dividends.
Warrants
The Warrants are exercisable for five years and six months from the earlier of
the maturity date of the Debentures and the closing of the Qualified Financing,
at an exercise price equal to (i) in the event that a Qualified Offering is
consummated prior to the exercise of the Warrant, the price per share at which
. . .
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an
Off-Balance Sheet Arrangement of a Registrant.
To the extent required by Item 2.03 of Form 8-K, the information contained in
Item 1.01 of this Current Report on Form 8-K is incorporated herein by
reference.
Item 8.01 Other Events.
On November 29, 2022, the Company issued a press release announcing the closing
of the Offering. A copy of the press release is included as Exhibit 99.1 to this
report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed as part of this report.
Exhibit No. Description
4.1 Form of 10% Original Issue Discount Senior Secured Convertible
Debentures*
4.2 Form of Common Stock Purchase Warrant*
4.3 Form of 10% Original Issue Discount Senior Secured Convertible
Debentures (Exchanged Debentures)*
10.1 Placement Agency Agreement by and between the Company and Joseph
Gunnar & Co.
10.2 Form of Securities Purchase Agreement*
10.3 Form of Security Agreement*
99.1 Press Release dated November 29, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
* Schedules, exhibits, and similar attachments have been omitted pursuant to Item
601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies of
such omitted materials supplementally upon request by the U.S. Securities and
Exchange Commission.
© Edgar Online, source Glimpses